Authors :
Bonaspur Srivani; Gandola Ashwini; Mangali Kalyani; Patheparupu Gopi Pavan Kumar,
Volume/Issue :
Volume 5 - 2020, Issue 6 - June
Google Scholar :
http://bitly.ws/9nMw
Scribd :
https://bit.ly/2ChGZ98
DOI :
10.38124/IJISRT20JUN1036
Abstract :
Antithrombotic therapy and Fibrinolytics
are central to the management of Acute Coronary
Syndrome. These are high alert medications that are
prone to adverse effects thus requiring strict
monitoring. Effective usage of these medications results
in reduction of recurrent ischaemic events including MI
and stent thrombosis. Reducing the ischemic events and
maintaining a balance between normal physiological
coagulability and the bleeding is vital to avoid bleeding
complications during the therapy. This therapy induced
adverse effects increases mortality and morbidity rate.
In our study we are mainly focussing on, comparing and
demonstrating the effectiveness of enoxaparin over
heparin and Tenecteplase over streptokinase and to
assess, evaluate and management of adverse events by
Narinjo assessment scale. Majority of adverse events
were seen in subjects with social history of alcoholism,
this shows alcoholism decreasing the threshold to
adverse events. Causality assessment of adverse effects
were 17.45% Possible and 91.6% were probable. The
streptokinase was found superior than tenecteplase and
enoxaparin was found superior than heparin in terms of
adverse events and hospitalisation period. ACS is an
drastic health disorder that increases the morbidity
rate, mortality rate, economic burden and well being of
the persons. Thus individualisation of drug regimen and
strategies for early detection, monitoring and
management of adverse events is mandatory.
Keywords :
Acute coronary syndrome, Fibrinolytics, Antithrombotics, Management.
Antithrombotic therapy and Fibrinolytics
are central to the management of Acute Coronary
Syndrome. These are high alert medications that are
prone to adverse effects thus requiring strict
monitoring. Effective usage of these medications results
in reduction of recurrent ischaemic events including MI
and stent thrombosis. Reducing the ischemic events and
maintaining a balance between normal physiological
coagulability and the bleeding is vital to avoid bleeding
complications during the therapy. This therapy induced
adverse effects increases mortality and morbidity rate.
In our study we are mainly focussing on, comparing and
demonstrating the effectiveness of enoxaparin over
heparin and Tenecteplase over streptokinase and to
assess, evaluate and management of adverse events by
Narinjo assessment scale. Majority of adverse events
were seen in subjects with social history of alcoholism,
this shows alcoholism decreasing the threshold to
adverse events. Causality assessment of adverse effects
were 17.45% Possible and 91.6% were probable. The
streptokinase was found superior than tenecteplase and
enoxaparin was found superior than heparin in terms of
adverse events and hospitalisation period. ACS is an
drastic health disorder that increases the morbidity
rate, mortality rate, economic burden and well being of
the persons. Thus individualisation of drug regimen and
strategies for early detection, monitoring and
management of adverse events is mandatory.
Keywords :
Acute coronary syndrome, Fibrinolytics, Antithrombotics, Management.
